Di Yi Cai Jing·2025-12-23 07:18Core Viewpoint - Fosun Pharma's proposed acquisition of Green Valley Pharmaceutical for 1.412 billion yuan has unexpectedly led to a significant decline in the company's stock price and triggered a regulatory inquiry from the Shanghai Stock Exchange [1] Group 1: Acquisition Details - The acquisition involves a total investment of 1.412 billion yuan aimed at acquiring Green Valley Pharmaceutical [1] - Fosun Pharma's response to the regulatory inquiry addressed the specifics of the transaction, the clinical progress of the Alzheimer's disease (AD) drug, and future integration plans [1] Group 2: Product Information - The key product involved in this acquisition is the mannitol sodium capsule, which is Green Valley Pharmaceutical's main offering [1] - This drug received conditional approval from the National Medical Products Administration in November 2019 for the treatment of mild to moderate Alzheimer's disease, marking it as the first AD treatment drug approved globally in 17 years since the approval of Donepezil in 2002 [1]